HC Wainwright Has Optimistic Opinion of RVMD FY2026 Earnings

Key Points

• HC Wainwright raised its FY2026 EPS estimate for Revolution Medicines to a loss of $7.42 per share from a projected loss of $9.20, while maintaining a Buy rating and $350 price target.
• HC Wainwright forecasts RVMD will reach positive EPS in Q3 2027 and post full-year 2027 EPS of $0.20. Analysts overall hold a Moderate Buy consensus rating, with an average price target of $263.15.
• Revolution Medicines reported a quarterly loss of $1.90 per share, beating the analyst consensus estimate of a $2.35 loss; revenue of $197.56 million also exceeded the $25.58 million consensus.

Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) - Equities research analysts at HC Wainwright lifted their FY2026 earnings per share estimates for Revolution Medicines in a research report issued on Friday, November 6th. HC Wainwright analyst R. Burns now expects that the company will post earnings per share of ($7.42) for the year, up from their prior estimate of ($9.20). HC Wainwright currently has a "Buy" rating and a $350.00 price target on the stock. The consensus estimate for Revolution Medicines' current full-year earnings is ($7.88) per share. HC Wainwright also issued estimates for Revolution Medicines' Q4 2026 earnings at ($1.02) EPS, Q1 2027 earnings at ($0.56) EPS, Q2 2027 earnings at ($0.14) EPS, Q3 2027 earnings at $0.37 EPS, Q4 2027 earnings at $0.52 EPS and FY2027 earnings at $0.20 EPS.

Other equities research analysts have also recently issued reports about the company. Truist Financial reiterated a "buy" rating and set a $261.00 target price (up from $241.00) on shares of Revolution Medicines in a research note on Thursday, November 5th. Evercore restated an "outperform" rating and set a $320.00 price target on shares of Revolution Medicines in a research report on Thursday, August 27th. Sanford C. Bernstein increased their price target on shares of Revolution Medicines from $151.00 to $179.00 and gave the company a "market perform" rating in a research report on Friday, August 21st. Wedbush raised their price objective on shares of Revolution Medicines from $201.00 to $225.00 and gave the stock an "outperform" rating in a report on Thursday, August 27th. Finally, Morgan Stanley began coverage on shares of Revolution Medicines in a research report on Thursday, September 10th. They issued an "overweight" rating and a $255.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $263.15.

Revolution Medicines Stock Up 4.1%

Shares of NASDAQ:RVMD opened at $200.15 on Tuesday. The company has a market capitalization of $42.90 billion, a PE ratio of -21.97 and a beta of 1.44. The company has a debt-to-equity ratio of 0.40, a current ratio of 11.38 and a quick ratio of 11.38. The business has a fifty day moving average price of $196.73 and a two-hundred day moving average price of $157.98. Revolution Medicines has a 1 year low of $61.50 and a 1 year high of $224.31.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last issued its quarterly earnings results on Wednesday, November 4th. The company reported ($1.90) EPS for the quarter, topping analysts' consensus estimates of ($2.35) by $0.45. The business had revenue of $197.56 million for the quarter, compared to the consensus estimate of $25.58 million. During the same quarter last year, the business posted ($1.61) earnings per share.

Insider Buying and Selling

In other Revolution Medicines news, Director Elizabeth M. Anderson sold 10,143 shares of the stock in a transaction on Tuesday, September 22nd. The stock was sold at an average price of $193.04, for a total transaction of $1,958,004.72. Following the sale, the director owned 4,333 shares in the company, valued at $836,442.32. This represents a 70.07% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Alan B. Sandler sold 6,309 shares of the firm's stock in a transaction on Tuesday, September 29th. The stock was sold at an average price of $202.14, for a total value of $1,275,301.26. Following the completion of the transaction, the insider directly owned 52,559 shares of the company's stock, valued at $10,624,276.26. The trade was a 10.72% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 290,991 shares of company stock worth $59,422,765 in the last 90 days. 7.60% of the stock is currently owned by company insiders.

Institutional Trading of Revolution Medicines

A number of institutional investors have recently added to or reduced their stakes in RVMD. Alphabet Inc. purchased a new position in Revolution Medicines during the 2nd quarter valued at about $551,843,000. Assenagon Asset Management S.A. lifted its holdings in shares of Revolution Medicines by 987.9% in the third quarter. Assenagon Asset Management S.A. now owns 2,181,185 shares of the company's stock worth $447,710,000 after buying an additional 1,980,699 shares in the last quarter. ABS Investment Management LLC purchased a new stake in shares of Revolution Medicines in the second quarter worth about $337,104,000. Bank of America Corp DE purchased a new stake in shares of Revolution Medicines in the second quarter worth about $184,267,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Revolution Medicines by 82.3% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 912,335 shares of the company's stock valued at $170,862,000 after acquiring an additional 411,740 shares during the period. Hedge funds and other institutional investors own 94.34% of the company's stock.

About Revolution Medicines

Revolution Medicines, Inc is a biotechnology company focused on developing targeted therapies for patients with RAS-driven cancers. Founded in 2014 and headquartered in Redwood City, California, the company's research centers on RAS proteins, which can contribute to the growth of many cancers.

The company's pipeline includes drug candidates designed to inhibit mutant RAS proteins, including daraxonrasib (RMC-6236), which targets multiple RAS variants, and candidates directed at specific KRAS mutations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.